To evaluate the safety, tolerability, and efficacy of chronic combination therapy with an angiotensin-converting enzyme (ACE) inhibitor and an angiotensin II receptor blocker (ARB) in the management of heart failure.
DATA SOURCES:
Clinical literature was accessed through MEDLINE (January 1966–June 2000). Key search terms included angiotensin-converting enzyme inhibitor; losartan; combined modality therapy; drug effects; heart failure, congestive; and receptors, angiotensin.
DATA SYNTHESIS:
Heart failure is widely prevalent and continues to be associated with high morbidity and mortality, even with currently recommended care. At the moderate doses studied for patients with mild heart failure in brief trials, combined ACE inhibitor and ARB therapy was well tolerated and had an additive effect in reducing blood pressure and relieving symptoms of heart failure.
CONCLUSIONS:
An ARB combined with an ACE inhibitor may benefit heart failure patients who are receiving all other recommended therapies. Further trials are needed to evaluate long-term safety, effectiveness, quality of life, and survival before the combination can be recommended for routine use.
PackerMPoole-WilsonPAArmstrongPWClelandJGHorowitzJDMassieBMComparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation1999;100:2312–8.
4.
HjalmarsonAGoldsteinSFagerbergBWedelHWaagsteinFKjekshusJEffects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure. The metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). JAMA2000;283:1295–302.
5.
PittBZannadFRemmeWJCodyRCastaigneAPerezAThe effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med1999;341:709–17.
6.
CohnJNJohnsonGZiescheSCobbFFrancisGTristaniFA comparison of enalapril with hydralazine—isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med1991;325: 303–10.
7.
PittBSegalRMartinezFAMeurersGCowleyAJThomasIRandomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly study, ELITE). Lancet1997;349:747–52.
8.
AHA: new study shows no survival advantage in heart-failure patients taking Cozaar compared to captopril. P/S/L Consulting Group Inc. November 10, 1999. Available at: URL: http://www.pslgroup.com/dg/144AE6.htm (accessed April 14, 2000).
9.
McKelvieRSYusufSPericakDAvezumABurnsRJProbstfieldJComparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation1999;100:1056–64.
10.
MungerMAFurnissSM. Angiotensin II receptor blockers: Novel therapy for heart failure?Pharmacotherapy1996;16(2 pt 2):59S–69S.
11.
GainerJ VMorrowJDLovelandAKingDJBrownNJ. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med1998;339:1285–92.
12.
RousseauMFKonstamMABenedictCRDonckierJGalantiLMelinJProgression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor. Am J Cardiol1994;73:488–93.
13.
CaliffRMCohnJ. Cardiac protection: Evolving role of angiotensin receptor blockers. Am Heart J2000;139(Suppl):S15–22.
14.
PittBDicksteinKBenedictCRPacherRWillenheimerRMuraliSThe Randomized Angiotensin receptor Antagonist—ACE inhibitor Study (RAAS) — Pilot study (abstract). Circulation1996;94(suppl I):I–428.
15.
TocchiMRosanioSAnzuiniASposiAMattioliD. Angiotensin II receptor blockade combined to ACE-inhibition improves left ventricular dilation and exercise ejection fraction in congestive heart failure (abstract). J Am Coll Cardiol1998;31:188A.
16.
HamroffGKatzSManciniDBlaufarbIBijouRPatelRAddition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation1999;99:990–2.
17.
TonkonMAwanNNiaziIHanleyPBaruchLWolfRAA study of the efficacy and safety of irbesartan in combination with conventional therapy, including ACE inhibitors, in heart failure. Int J Clin Pract2000;54:11–8.
18.
GuazziMPalermoPPontoneGSusiniFAgostoniP. Synergistic efficacy of enalapril and losartan on exercise performance and oxygen consumption at peak exercise in congestive heart failure. Am J Cardiol1999;84:1038–43.
19.
BaruchLAnandICohenISZiescheSJuddDCohnJNAugmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Circulation1999;99:2658–64.
20.
HamroffGBlaufarbIManciniDKatzSDBijouRJondeauGAngiotensin-II receptor blockade further reduces afterload safely in patients maximally treated with angiotensin-converting enzyme inhibitors for heart failure. J Cardiovasc Pharmacol1997;30:533–6.
21.
SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med1991;325:293–302.
